All In Biotech

Drug Trial Radar · NCT00337103

E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes

A Phase III Open Label, Randomized Two-Parallel-Arm Multicenter Study of E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes

Last checked: Nov 19, 2026Latest source record: Jun 18, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,276 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,276

Actual

Start

Sep 20, 2006

Primary completion

Mar 12, 2012

Study completion Dec 11, 2017

Sponsor

Lead sponsor
Eisai Inc.Eisai
Sponsor type
Industry
First posted
Jun 15, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare E7389 versus capecitabine in patients with locally advanced or metastatic breast cancer who are refractory to the most recent chemotherapy. This is an open-label, randomized, two-parallel arm study. Patients will be randomized to receive either E7389 or capecitabine on a one-to-one ratio.

Conditions

  • Metastatic Breast Cancer

Interventions

  • Eribulin MesylateDrug

    1.4 mg/m\^2 intravenous (IV) infusion given over 2-5 minutes on Days 1 and 8 every 21 days

  • CapecitabineDrug

    Capecitabine 2.5 g/m\^2/day administered orally twice daily in two equal doses on Days 1 to 14 every 21 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS)Time frame: From date of randomization until date of death from any cause, assessed up to data cutoff date of 12 Mar 2012, or up to approximately 6 years
  2. Progression Free Survival (PFS)Time frame: From date of randomization to the date of disease progression or death (whichever occurred first), assessed up to data cutoff date of 12 Mar 2012 or up to approximately 6 years

Locations

169 sites in 23 countries. Site status is shown where the registry gives one.

  • Site not named

    Anaheim, California

  • Site not named

    La Verne, California

  • Site not named

    Poway, California

  • Site not named

    Centralia, Illinois

  • Site not named

    Augusta, Maine

  • Site not named

    Boston, Massachusetts

  • Site not named

    Jefferson City, Missouri

  • Site not named

    Lebanon, New Hampshire

  • Site not named

    Ephrata, Pennsylvania

  • Site not named

    Cookeville, Tennessee

  • Site not named

    Germantown, Tennessee

  • Site not named

    Amarillo, Texas

  • Site not named

    Wenatchee, Washington

  • Site not named

    Bahía Blanca, Argentina

  • Site not named

    Buenos Aires, Argentina

  • Hospital Italiano de Buenos Aires

    Buenos Aires, Argentina

  • Site not named

    Buenos Aires, Argentina

  • Site not named

    Ciudad Autonoma, Argentina

  • Site not named

    Mendoza, Argentina

  • Site not named

    Santa Fe, Argentina

  • Hospital General de Agudos Teodoro Alvarez

    Ciudad Autonoma, Buenos Aires, Argentina

  • Instituto Argentino de Diagnostico y Tratamiento

    Cuidad Autonoma de Buenos Aires, Buenos Aires, Argentina

  • Site not named

    La Plata, Buenos Aires, Argentina

  • Site not named

    La Plata, Buenos Aires, Argentina

  • Site not named

    Pilar, Buenos Aires, Argentina

  • Corporacion Medica General San Martin

    San Martín, Buenos Aires, Argentina

  • Site not named

    Rosario, Santa Fe Province, Argentina

  • Site not named

    San Miguel de Tucumán, Tucumán Province, Argentina

  • Epworth Freemasons Hospital

    East Melbourne, Australia

  • Sir Charles Gairdner Hospital, Dept. of Medical Oncology

    Nedlands, Australia

  • Mater Adult Hospital

    South Brisbane, Australia

  • Bankstown Hospital, Oncology Trials Unit

    Bankstown, New South Wales, Australia

  • Site not named

    Hornsby, New South Wales, Australia

  • Liverpool Hospital, Cancer Therapy Centre

    Liverpool, New South Wales, Australia

  • Ashford Cancer Centre

    Adelaide, South Australia, Australia

  • Royal Hobart Hospital

    Hobart, Tasmania, Australia

  • Saint Vincent's Hospital

    Fitzroy, Victoria, Australia

  • Royal Perth Hospital

    Perth, Western Australia, Australia

  • OLVZ Aalst, Oncology Service

    Aalst, Belgium

  • Institut Jules Bordet, Medical Oncology Unit

    Brussels, Belgium

Showing 40 of 169 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.